Avibactam is a non-β-Lactam β-Lactamase developed by Actavis (now Teva) jointly with AstraZeneca. A new drug application for avibactam in combination with ceftazidime (branded as Avycaz) was approved by the FDA on February 25, 2015, for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic resistant pathogens including those caused by multi-drug resistant gram-negative bacterial pathogens.
Antibiotics & Antibacterials
|Storage Conditions||-18 deg C|
|MDL Number||Request if not shown|
Send us your enquiry for Avibactam Sodium. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Avibactam Sodium email us and we will include your contribution on the website.